CAM
LAB icon

Connacht Asset Management’s Standard BioTools LAB Stock Holding History

Connacht Asset Management’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-190,900
Closed -$863K – 131
2021
Q1 		$863K Buy
+190,900
New +$1.05M 0.19% 98

Other funds holding LAB

ICM
Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Connacht Asset Management's LAB Position: Q4 2021 in Review

Connacht Asset Management sold out of Standard BioTools (LAB) in Q4 2021, closing a stake of 65,065 shares — an estimated $429K sold.

Connacht Asset Management first reported a position in LAB in Q4 2020 and held it in 4 quarters. The position peaked at $1.44M in Q4 2020. 121 funds tracked by Wall St. Rank hold LAB as of Q4 2021.

  • Connacht Asset Management reported no remaining Standard BioTools position as of Q4 2021 after selling out during the quarter.
  • Connacht Asset Management sold 65,065 Standard BioTools shares in Q4 2021, an estimated $429K.
  • Connacht Asset Management first reported a position in Standard BioTools in Q4 2020 and held it in 4 quarters.
  • Connacht Asset Management's Standard BioTools position peaked at $1.44M in Q4 2020.
  • 121 funds tracked by Wall St. Rank held Standard BioTools as of Q4 2021.

Based on Connacht Asset Management's 13F filing for Q4 2021, filed 11 Feb 2022.